364 related articles for article (PubMed ID: 18586919)
1. Is there an entity of chemically induced BCR-ABL-positive chronic myelogenous leukemia?
Lichtman MA
Oncologist; 2008 Jun; 13(6):645-54. PubMed ID: 18586919
[TBL] [Abstract][Full Text] [Related]
2. Dangerous and cancer-causing properties of products and chemicals in the oil refining and petrochemical industries. Part XXX: Causal relationship between chronic myelogenous leukemia and benzene-containing solvents.
Mehlman MA
Ann N Y Acad Sci; 2006 Sep; 1076():110-9. PubMed ID: 17119196
[TBL] [Abstract][Full Text] [Related]
3. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
[TBL] [Abstract][Full Text] [Related]
4. Effect of interferon-alpha on chromosome abnormalities in treated chronic myelogenous leukemia patients.
Tanaka H; Tanaka K; Oguma N; Ito K; Ito T; Kyo T; Dohy H; Kimura A
Cancer Genet Cytogenet; 2004 Sep; 153(2):133-43. PubMed ID: 15350303
[TBL] [Abstract][Full Text] [Related]
5. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
6. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Chien JH; Tang JL; Chen RL; Li CC; Lee CP
Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
[TBL] [Abstract][Full Text] [Related]
7. The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias.
Williams RT; Sherr CJ
Cold Spring Harb Symp Quant Biol; 2008; 73():461-7. PubMed ID: 19028987
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
9. Occurrence of the same chromosome abnormalities in Ph+ and Ph- cells in chronic myeloid leukaemia. Evidence of a secondary origin of the Ph chromosome?
Donti E; Zaccaria A; Bassetti A; Venti G; Giannini B; Prontera P; Bianchi E; Valenti A; Saglio G; Liberati AM
Br J Haematol; 2006 Oct; 135(2):265-6. PubMed ID: 16956349
[No Abstract] [Full Text] [Related]
10. Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells.
Mao X; Yu CR; Li WH; Li WX
Cell Res; 2008 Aug; 18(8):879-88. PubMed ID: 18663379
[TBL] [Abstract][Full Text] [Related]
11. [Cytogenetic characteristics of H3 oxide induced myeloid leukemia in Wistar rats].
Nikolaevskaia NG; Muksinova KN; Murzina LD; Revina VS
Eksp Onkol; 1990; 12(3):19-21. PubMed ID: 2344818
[TBL] [Abstract][Full Text] [Related]
12. Cancer cytogenetics and molecular genetics: detection and therapeutic strategy.
Sandberg AA; Chen Z
In Vivo; 1994; 8(5):807-18. PubMed ID: 7727729
[TBL] [Abstract][Full Text] [Related]
13. Chronic myelogenous leukemia following radiotherapy and chemotherapy for non-Hodgkin lymphoma.
Cazzola M; Bergamaschi G; Melazzini M; Ponchio L; Rosti V; Molinari E
Haematologica; 1990; 75(5):477-9. PubMed ID: 2097266
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase I inhibitors in the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia.
Beran M
Leuk Res; 2004 May; 28(5):443-6. PubMed ID: 15068895
[No Abstract] [Full Text] [Related]
15. A case of chronic myelogenous leukemia with e8a2 fusion transcript.
Park IJ; Lim YA; Lee WG; Park JS; Kim HC; Lee HJ; Cho SR
Cancer Genet Cytogenet; 2008 Sep; 185(2):106-8. PubMed ID: 18722880
[TBL] [Abstract][Full Text] [Related]
16. [Abnormalities of chromosome 17 in myeloid malignancies with complex chromosomal abnormalities].
Zhu Y; Xu W; Liu Q; Pan J; Qiu H; Wang R; Qiao C; Jiang Y; Zhang S; Fan L; Zhang J; Shen Y; Xue Y; Li J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Oct; 25(5):579-82. PubMed ID: 18841577
[TBL] [Abstract][Full Text] [Related]
17. Therapy-related acute leukemia.
Karp JE; Sarkodee-Adoo CB
Clin Lab Med; 2000 Mar; 20(1):71-81, ix. PubMed ID: 10702897
[TBL] [Abstract][Full Text] [Related]
18. Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia.
Kim M; Lee S; Jung CK; Lim J; Cho SG; Kim DW; Kim Y; Han K; Min WS; Kim CC
Int J Lab Hematol; 2008 Dec; 30(6):508-12. PubMed ID: 18983302
[TBL] [Abstract][Full Text] [Related]
19. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia.
Al-Kali A; Farooq S; Tfayli A
J Clin Pharm Ther; 2009 Oct; 34(5):607-10. PubMed ID: 19744017
[TBL] [Abstract][Full Text] [Related]
20. [Therapy of chronic myeloid leukemia. Uncommon view of the modern approaches].
Mayer J; Zácková D; Klamová H; Doubek M
Cas Lek Cesk; 2008; 147(4):206-10. PubMed ID: 18578373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
